Current management of chemotherapy-induced neutropenia: The role of colony-stimulating factors

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 13, 2003, Pages 3-9

  Dale, David ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEVER; HEMATOPOIETIC SYSTEM; HUMAN; INCIDENCE; INFECTION; MEDICAL PRACTICE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 0141813695     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00326-9     Document Type: Article

References (44)

1. American Cancer Society: Cancer facts and figures. Atlanta, GA, American Cancer Society, 2003
2. National Cancer Institute, National Institutes of Health, Department of Health and Human Services: Common toxicity criteria, version 2.0. 1999. Available at: http://ctep.info.nih.gov (accessed July 17, 2003)
3. Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751, 2002
4. Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340, 1966
5. Meza L, Baselga J, Holmes FA, et al: Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy. Proc Am Soc Clin Oncol 21:255b, 2002 (abstr 2840)
6. Kuderer NM, Cosler L, Crawford J, et al: Cost and mortality associated with febrile neutropenia in adult cancer patients. Proc Am Soc Clin Oncol 21:250a, 2002 (abstr 998)
7. Balducci L, Extermann M: Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 14:1-16, 2000
8. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558-3585, 2000
9. Dale DC, Crawford J, Lyman GH: Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: An evidence-based review. Proc Am Soc Clin Oncol 20:410a, 2001 (abstr 1638)
10. Caggiano V, Stolshek B, Delgado D, et al: First and all cycle febrile neutropenia hospitalizations (FNH) and costs in intermediate grade non-Hodgkins lymphoma (IGL) patients on standard dose CHOP therapy. Blood 98:431a, 2001 (abstr 1810)
11. Gomez H, Hidalgo M, Casanova L, et al: Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis. J Clin Oncol 16:2065-2069, 1998
12. Lyman GH, Morrison VA, Dale DC, et al: Risk of first febrile neutropenia (FN) among patients receiving CHOP chemotherapy. Proc Am Soc Clin Oncol 21:358a, 2002 (abstr 1430)
13. Gandhi SK, Arguelles L, Boyer JG: Economic impact on neutropenia and febrile neutropenia in breast cancer: Estimates from two national databases. Pharmacotherapy 21:247b, 2001 (abstr 2808)
14. Lyman GH, Kuderer NM: Filgrastim in patients with neutropenia: Potential effects on quality of life. Drugs 62:65-78, 2002 (suppl 1)
15. Lyman GH, Kuderer N, Greene J, et al: The economics of febrile neutropenia: Implications for the use of colonys-timulating factors. Eur J Cancer 34:1857-1864, 1998
16. Cosler LE, Agboola O, Calhoun EA, et al: An updated risk threshold model for G-CSF prophylaxis use in cancer chemotherapy: Incorporation of patient out-of-pocket and indirect costs. International Society for Pharmacoeconomics and Outcomes Research 7th Annual Meeting, May 19-22, 2002. Arlington, VA. Value Health 5:138, 2002 (abstr)
17. Fortner B, Solshek B, Tauer KW, et al: Chemotherapy-induced neutropenia (CIN) is associated with lower quality of life in patients with cancer. Ann Oncol 13:174, 2002 (suppl 15)
18. Okon TA, Fortner BV, Schwartzberg L, et al: Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN). Proc Am Soc Clin Oncol 21:275b, 2002 (abstr 2920)
19. Calhoun EA, Chang CH, Welshman EE, et al: A neutropenia-specific quality of life instrument: Rationale for the development of the FACT-N. Proc Am Soc Clin Oncol 21: 375a, 2002 (abstr 1498)
20. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 332:901-906, 1995
21. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205-1211, 1998
22. Kwak LW, Halpern J, Olshen RA, et al: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 8:963-977, 1990
23. Epelbaum R, Faraggi D, Ben-Arie Y, et al: Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 66:1124-1129, 1990
24. Lepage E, Gisselbrecht C, Haioun C, et al: Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 4:651-656, 1993
25. Chrischilles E, Link B, Scott S, et al: Factors associated with early termination of CHOP, and its association with overall survival among patients with intermediate-grade non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 21:385a, 2002 (abstr 1539)
26. Dale DC, McCarter GC, Crawford J, et al: Myelotoxicity and dose intensity of chemotherapy: Reporting practices from randomized clinical trials. J Natl Comp Cancer Network 2003 (in press)
27. Link BK, Budd GT, Scott S, et al: Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: Current patterns of care. Cancer 92:1354-1367, 2001
28. Agboola O, Crawford J, Dale D, et al: Most patients treated with adjuvant chemotherapy for breast cancer receive substantially reduced dose intensity: Results of a practice pattern survey of nearly 20,000 patients. Proc Am Soc Clin Oncol 22:28, 2003 (abstr 110)
29. Neupogen (filgrastim) prescribing information. Amgen, Thousand Oaks, CA, 2001
30. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
31. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
32. Meza L, Hackett J, Neumann T: Time to absolute neutrophil count (ANC) recovery in patients with breast cancer. Poster presented at the Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, NM, October 20, 2002
33. Scott SD, Chrischilles EA, Link BK, et al: Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manage Care Pharm 9:15-21, 2003 (suppl 2)
34. Crawford J: Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev 28:7-11, 2002 (suppl A)
35. Crawford J: Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy- induced neutropenia. Semin Oncol 30:24-30, 2003 (suppl 13)
36. Holmes FA, Jones SE, O'Shaughnessy J, et al: Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia. A multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903-909, 2002
37. Holmes FA, O'Shaughnessy JA, Vukelja S, et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731, 2002
38. Green MD, Koelbl H, Baselga J, et al: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35, 2003
39. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
40. de Graaf H, Willemse PH, Bong SB, et al: Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology 53:289-294, 1996
41. Rivera E, Erder MH, Moore TD, et al: Targeted filgrastim support in patients with early-stage breast carcinoma: Toward the implementation of a risk model. Cancer 98:222-228, 2003
42. Lyman GH, Kuderer NM, Djulbegovic B: Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis. Am J Med 112:406-411, 2002
43. Pfreundschuh M, Trumper L, Kloess M, et al: 2-weekly vs 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): Results of the completed NHL-B-2 trials of the DSHNHL. Blood 100:774a, 2002 (abstr 3060)
44. Citron ML, Berry MA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21:1431-1439, 2003